Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Dementia: A Pilot Study

• Published in: International journal of molecular sciences 2024-08, Vol.25 (15), p.8354
• Main Authors: Saraceno, Claudia, Cervellati, Carlo, Trentini, Alessandro, Crescenti, Daniela, Longobardi, Antonio, Geviti, Andrea, Bonfiglio, Natale Salvatore, Bellini, Sonia, Nicsanu, Roland, Fostinelli, Silvia, Mola, Gianmarco, Riccetti, Raffaella, Moretti, Davide Vito, Zanetti, Orazio, Binetti, Giuliano, Zuliani, Giovanni, Ghidoni, Roberta
• Format: Article
• Language: English
• Subjects: Advertising executives; Age; Aged; Alzheimer Disease - blood; Alzheimer Disease - diagnosis; Alzheimer's disease; Amyloid beta-protein; Amyloid Precursor Protein Secretases - blood; Amyloid Precursor Protein Secretases - metabolism; Aspartic Acid Endopeptidases - blood; BACE1; Biomarkers; Biomarkers - blood; Brain; Case-Control Studies; Cognitive ability; Dementia; Development and progression; Diagnosis; Diagnosis, Differential; Disease; Diseases; Enzymes; Female; frontotemporal dementia; Frontotemporal Dementia - blood; Frontotemporal Dementia - diagnosis; Gender; Generalized linear models; GFAP; Glial Fibrillary Acidic Protein - blood; Humans; Male; Middle Aged; Neurofilament Proteins - blood; NfL; Older people; Pilot Projects; Plasma; Proteins; serum
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25158354

Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the two major neurodegenerative diseases causing dementia. Due to similar clinical phenotypes, differential diagnosis is challenging without specific biomarkers. Beta-site Amyloid Precursor Protein cleaving enzyme 1 (BACE1) is a β-secretase pivotal in AD pathogenesis. In AD and mild cognitive impairment subjects, BACE1 activity is increased in brain/cerebrospinal fluid, and plasma levels appear to reflect those in the brain. In this study, we aim to evaluate serum BACE1 activity in FTD, since, to date, there is no evidence about its role. The serum of 30 FTD patients and 30 controls was analyzed to evaluate (i) BACE1 activity, using a fluorescent assay, and (ii) Glial Fibrillary Acid Protein (GFAP) and Neurofilament Light chain (NfL) levels, using a Simoa kit. As expected, a significant increase in GFAP and NfL levels was observed in FTD patients compared to controls. Serum BACE1 activity was not altered in FTD patients. A significant increase in serum BACE1 activity was shown in AD vs. FTD and controls. Our results support the hypothesis that serum BACE1 activity is a potential biomarker for the differential diagnosis between AD and FTD.